Rivaroxaban demonstrates non-inferiority, halves major bleeding risk

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1395, 2012-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modified HAS-BLED Score and Risk of Major Bleeding in Patients Receiving Dabigatran and Rivaroxaban: A Retrospective, Case-Control Study

By Tsu Laura V.   Berry Andrew   Wald Erin   Ehrlich Cassandra  

The Consultant Pharmacist, Vol. 30, Iss. 7, 2015-07 ,pp. : 395-402

American Society of Consultant Pharmacists

Access to resources Recommend Favorite

Understanding Non‐Inferiority Trials – A Different Type of Evidence

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 1, 2011-03 ,pp. : 16-17

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk of major bleeding with apixaban in ACS

By  

Reactions Weekly, Vol. 1, Iss. 1363, 2011-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

A Ratio Test in Active Control Non-Inferiority Trials with a Time-to-Event Endpoint

By Wang Yong-Cheng  

Journal of Biopharmaceutical Statistics, Vol. 16, Iss. 2, 2006-03 ,pp. : 151-164

Taylor & Francis Ltd

Access to resources Recommend Favorite

Major bleeding: management and risk reduction in acute coronary syndromes

By Cavender Matthew A   Rao Sunil V   Ohman E Magnus  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 11, 2008-08 ,pp. : 1869-1883

Informa Healthcare

Access to resources Recommend Favorite